Abstract
Metformin has been known to the mankind for centuries. Metformin is the first line of drug of choice for the treatment of type 2 diabetes. Initial pharmaceutical therapy was for treating the frequent urinal problem which is a primary manifestation of diabetes. At the time of writing, metformin as an intervention is looked into for cardiovascular risks, polycystic ovary syndrome and breast cancer. Annual demand for Metformin is 23,000 Metric tons per annum. Nano Drug Delivery Systems (NDDS) has embarked into Metformin controlled and targeted delivery for breast cancer, pancreatic cancer and non-small cell lung cancer. Clinical estimation of the biological fluids by the FDA approved diagnostic laboratories use LC-MS/MS where blood samples estimate Metformin as an intact molecule easing the pressure of clinical trials result. Metformin was manufactured by a less known and low profile Aoron pharmaceutical, France not aware of the block buster drug hence the potential of technology development start-ups can neither be underwritten nor underestimated even when there is a very high rate (~90%) of failed biotech/biomed start-up ventures. The bloom of the French lilac (metformin) to blossom and flower for the cure of breast cancer by convergence revolution initiative with the integration of academia, hospital, technology business incubator, multinational corporation with the deliverance of a start-up company
Highlights
Metformin is the oral antihyperglycaemic drug of choice for type 2 diabetes mellitus treatment
The action of metformin on cancer cell proliferation is associated with AMPK activation, reduced Mammalian Target of Rapamycin signaling and protein synthesis, as well as a variety of other responses including decreased epidermal growth factor receptor (EGFR), Src, and mitogen-activated protein kinase (MAPK) activation, decreased expression of cyclins, and increased expression of p2728,29
With supporting evidences based on several clinical trials, it is practically evident that metformin is used as a chemotherapeutic agent for tumor growth suppression (NCT0131023157, NCT0093057958) on breast cancer patients
Summary
Metformin is the oral antihyperglycaemic drug of choice for type 2 diabetes mellitus treatment This drug is unique from other oral antihyperglycaemic agents in the sense that this drug of choice subdues hepatic glucose production, reduces the intestinal glucose absorption and to a further extent improves insulin sensitivity. 70 Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative business incubator, philanthropic foundation and startup company with the best ability to forge a new innovative initiative path for the technology development for the cure of breast cancer This is very much depicted by the authors of this article who are chemical engineers, bioengineers, design engineers, biotechnologists, design engineer medical practitioners (both specialized and budding), philanthropists, technology developers and big data analysts. The plant is called as goat’s rue, French lilac (Figure 1), Spanish sanfoin and false indigo
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
